Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market, By Drugs (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), Brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Specialty Clinics, Others) - Industry Trends and Forecast to 2029.
Market Analysis and Insights
Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) are well-known as effective therapy for type 2 diabetes. GLP-1 RAs stimulate GLP-1 receptors, which increase insulin production and decrease glucagon release. Although all GLP-1 RAs work in the same way, they differ in terms of formulations, administration, injectable methods, and dosages. With six GLP-1 RAs currently available in Europe (immediate-release exenatide, lixisenatide, liraglutide; prolonged-release exenatide, dulaglutide, and semaglutide), each with their own characteristics and administration requirements, physicians caring for patients in their routine practise face the challenge of being aware of all of this information so they can select the agent that is most suitable for their patient and use it in an efficient and optimal manner
The glucagon-like peptide 1 (GLP-1) agonists is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the glucagon-like peptide 1 (GLP-1) agonists market was valued at 12.55 billion in 2021 and is likely to reach USD 20.15 billion by 2029, and will grow at a CAGR of 6.10% during the forecast period of 2022 to 2029.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Drugs (Exenatide, Liraglutide, Dulaglutide, Lixisenatide), Brand (Byetta, Bydureon, Victoza, Trulicity, Lyxumia), Route of Administration (Oral, Parenteral, Others), End Users (Hospitals, Specialty Clinics, Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (US), AstraZeneca (UK), Pfizer Inc (US), Baxter (US), Hikma Pharmaceuticals plc (UK), Amneal Pharmaceuticals, LLC (US), Teva Pharmaceuticals Industries Ltd (Israel), Sun Pharmaceuticals Industries Ltd (India), Mylan N.V. (US), Fresenius Kabi AG (Germany). |
|
Market Opportunities |
|
Glucagon-Like Peptide 1 (GLP-1) Agonists Market Dynamics
Drivers
Major factors that are expected to boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the forecast period are as follows:
- Rise in the cases of type 2 diabetes, obesity and related disorders
The overall influence of individual-level factors, such as the population's increasing median age and health factors, such as rising obesity and inactivity rates among people, has resulted in an increase in the diabetes population over time.
- Growing adaptation of unhealthy lifestyle and genetic history of diabetes disorders
Rise in the hectic lifestyle and unbalanced food diet and the hereditary history of diabetes disorders which upsurges the danger of growing diabetes.
- The obtainability of the treatment
Growing number of middle-class households, rise in the per capita income and increasing expenditure are one of the main contributors of the market growth.
Opportunities
In addition, the enhanced healthcare infrastructure, technological developments, and the accessibility of skilled medical professionals will further provide potential opportunities for the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the coming years.
Restraints/Challenges
On the flip side, strict FDA and other regulatory guidelines for the approval of new drug is further projected to impede he growth of the glucagon-like peptide 1 (GLP-1) agonists market in the timeline period. However, the dearth of suitable insurance policies might further challenge the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the near future.
This glucagon-like peptide 1 (GLP-1) agonists market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on glucagon-like peptide 1 (GLP-1) agonists market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The glucagon-like peptide 1 (GLP-1) agonists market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Covid-19 Impact on Glucagon-Like Peptide 1 (GLP-1) Agonists Market
The COVID-19 has positively affected the glucagon-like peptide 1 (GLP-1) agonists market. During the lockdowns and isolation during the pandemic complicated the diabetes management and medication adherence. Glucagon-like peptide 1 (GLP-1) agonists market promises due to its anti-inflammatory and anti-obesogenic qualities, as well as pulmonary protection and a positive impact on gut microbiota composition. Taking everything into account, glucagon-like peptide 1 (GLP-1) agonists market appear to be promising options for the treatment of COVID-19-infected patients with or without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) medications during COVID-19 pandemics.
Recent Development
- In November 2021, the Preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors was presented at ObesityWeek 2021, according to Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.
Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market Scope
The glucagon-like peptide 1 (GLP-1) agonists market is segmented on the basis of drugs, brand, route of administration and end users. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
On the basis of drugs, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into exenatide, liraglutide, dulaglutide, lixisenatide.
Brand
- Byetta
- Bydureon
- Victoza
- Trulicity
- Lyxumia
On the basis of brand, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into byetta, bydureon, victoza, trulicity, lyxumia.
Route of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into oral, parenteral, others.
End Users
- Hospitals
- Specialty Clinics
- Others
On the basis of end users, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into hospitals, specialty clinics, others.
Glucagon-Like Peptide 1 (GLP-1) Agonists Market Regional Analysis/Insights
The glucagon-like peptide 1 (GLP-1) agonists market is analysed and market size insights and trends are provided by country, drugs, brand, route of administration and end users as referenced above.
The countries covered in the glucagon-like peptide 1 (GLP-1) agonists market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the glucagon-like peptide 1 (GLP-1) agonists market due to the rise in the healthcare. Furthermore, the growing research and development. Furthermore, the occurrence of major key players will further boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the region during the forecast period. Asia-Pacific projected to observe significant amount of growth in the glucagon-like peptide 1 (GLP-1) agonists market due to the rise in the incidence cases of diabetes and other related disorders. Moreover, the growing number of generic drugs is anticipated to propel the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Glucagon-Like Peptide 1 (GLP-1) Agonists Market Share Analysis
The glucagon-like peptide 1 (GLP-1) agonists market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to glucagon-like peptide 1 (GLP-1) agonists market.
Some of the major players operating in the glucagon-like peptide 1 (GLP-1) agonists market are:
- Lilly (US)
- Novo Nordisk A/S (Denmark)
- AstraZeneca (US)
- Sanofi (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
